Please assess the completion status of the following clinical trial:

Trial Title: Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects enrolled in this study are required to meet the following inclusion criteria:~  1. Patients between 18 and 75 years of age.~ 2. Patients with histologically or cytologically diagnosed NSCLC,or patients with recurrent advanced NSCLC after surgery.~ 3. Harboring activating mutation of EGFR,only including an exon 19 deletion or an exon 21 point mutation.~ 4. Has at least one measureable lesion by RECIST 1.1~ 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~ 6. No prior systemic chemotherapy or targeted therapy for lung cancer before screening except neoadjuvant or adjuvant patients.~ 7. Adequate organ function, including the following:~     Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) ≥1.5 × 109/L,platelets ≥100 × 109/L,and hemoglobin ≥9 g/dL.~     Hepatic: bilirubin ≤1.5 times the upper limit of normal (× ULN),alkaline phosphatase (AP),aspartate transaminase (AST),and alanine transaminase (ALT) ≤3.0 × ULN (AP,AST and ALT ≤5 × ULN is acceptable if the liver has tumor involvement).~     Renal: calculated creatinine clearance (CrCl) ≥45 mL/minute based on the standard Cockcroft and Gault formula.~ 8. Prior radiation therapy allowed to \<25% of the bone marrow. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study enrolment.~ 9. Signed informed consent document on file.~ 10. Estimated life expectancy of ≥12 weeks.~ 11. Patient compliance and geographic proximity that allow adequate follow up.~      Exclusion Criteria:~* Subjects meeting any of the following exclusion criteria are not to be enrolled in the study.~  1. Known severe hypersensitivity to gefitinib.~ 2. Known brain metastasis unless asymptomatic brain metastasis(without neurotic symptoms and sign) and treated with surgery and/or radiation and stable without steroid treatment for at least 2 weeks prior to the first dose of study medication.~ 3. Pleural effusion or pericardiac effusion that cannot be controlled by drainage or other procedures.~ 4. Previous treatment with agents targeting the HER axis.~ 5. Previous systemic antitumour treatment.~ 6. The last regimen of neoadjuvant or adjuvant treatment for non-metastatic disease within 12 months of study treatment.~ 7. EGFR Resistance mutation (+).~ 8. Surgery undertaken less than 4 weeks before the study.~ 9. Inability to comply with protocol or study procedures.~ 10. A serious concomitant systemic disorder that,in the opinion of the investigator，would compromise the patient's ability to complete the study.~ 11. A serious cardiac condition,such as myocardial infarction within 6 months,angina,or heart disease.~ 12. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment.~ 13. Past medical history of Interstitial Lung Disease(ILD),drug induced interstitial disease,radiation pneumonitis which required steroid treatment,or any evidence of clinically active ILD.~ 14. Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.~ 15. Unwillingness to use contraception during the study, women who were pregnant or lactating.~ 16. Being or planing to participate in other studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days
- Arm B (Type: ACTIVE_COMPARATOR): Gefitinib 250mg/d until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).